Aldrich syndrome

Aldrich Syndrome

Aldrich Syndrome, more commonly known as Wiskott-Aldrich Syndrome (WAS), is a rare X-linked recessive immunodeficiency disorder characterized by a triad of symptoms: eczema, thrombocytopenia (low platelet count), and recurrent infections due to immunodeficiency. This condition primarily affects males, as it is linked to mutations in the WAS gene located on the X chromosome.

Clinical Features[edit]

The clinical presentation of Aldrich Syndrome is variable, but the hallmark features include:

Eczema: Patients often present with atopic dermatitis, which can be severe and difficult to manage.
Thrombocytopenia: This is often the first sign of the disease, with patients exhibiting petechiae, bruising, and an increased risk of bleeding due to low platelet counts.
Recurrent Infections: Due to the immunodeficiency, patients are susceptible to bacterial, viral, and fungal infections. Common infections include otitis media, pneumonia, and sepsis.

Pathophysiology[edit]

Aldrich Syndrome is caused by mutations in the WAS gene, which encodes the Wiskott-Aldrich Syndrome protein (WASP). WASP is crucial for the function of hematopoietic cells, including T cells, B cells, and platelets. Mutations in the WAS gene lead to defective actin cytoskeleton reorganization, affecting cell signaling, migration, and immune synapse formation.

Diagnosis[edit]

Diagnosis of Aldrich Syndrome is based on clinical findings, family history, and laboratory tests. Key diagnostic tests include:

Complete Blood Count (CBC): Reveals thrombocytopenia and small platelets.
Immunological Tests: Show abnormalities in T and B cell function.
Genetic Testing: Confirms mutations in the WAS gene.

Treatment[edit]

Management of Aldrich Syndrome involves supportive care and definitive treatment:

Supportive Care: Includes platelet transfusions, antibiotics for infections, and topical treatments for eczema.
Immunoglobulin Replacement Therapy: Helps prevent infections.
Hematopoietic Stem Cell Transplantation (HSCT): The only curative treatment, which can restore normal immune function.

Prognosis[edit]

The prognosis for patients with Aldrich Syndrome has improved with advances in treatment, particularly with the use of HSCT. Early diagnosis and intervention are crucial for improving outcomes.

Also see[edit]